NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurocrine Biosciences Inc (NBIX) is not an immediate buy for a beginner investor with a long-term focus. While the company has strong financial performance and positive developments in its product pipeline, the technical indicators suggest a mixed trend, and there is no strong proprietary trading signal to support an immediate entry. Additionally, options data indicates a cautious sentiment, and the stock's recent trend suggests potential short-term downside. A patient investor may wait for a better entry point or further confirmation of upward momentum.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 68.425, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a resistance level (R1: 132.313, R2: 134.185), which could limit immediate upside potential.
Strong financial performance in Q4 2025 with revenue up 28.33% YoY and net income up 49.08% YoY. Positive developments in the company's product pipeline, particularly with Ingrezza and Crenessity. Analyst sentiment remains largely positive, with multiple 'Buy' and 'Outperform' ratings.
Bearish technical indicators and mixed price target adjustments by analysts. Options data suggests cautious sentiment. Stock trend analysis indicates a potential short-term decline (-3.36% in the next week, -2.25% in the next month).
In Q4 2025, Neurocrine reported strong financial growth: Revenue increased by 28.33% YoY to $805.5M, net income rose by 49.08% YoY to $153.7M, and EPS grew by 48.00% YoY to 1.48. However, gross margin slightly declined by -0.71% YoY to 97.82.
Analysts have a generally positive outlook on NBIX. JPMorgan recently raised its price target to $177, citing strong uptake of Crenessity. Wolfe Research initiated coverage with an Outperform rating and a $160 price target. However, some analysts have lowered price targets slightly, reflecting cautious optimism.
